Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Effects of CD101 and fluconazole on adhesion-phase C. albicans biofilms (prevention). Effects of CD101 (0.25 or 1 μg/ml) (A) and fluconazole (1 or 4 μg/ml) (B) on the metabolic activity of C. albicans biofilms compared to that of the untreated controls. *, P value for comparison with the untreated control.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques: Activity Assay, Comparison, Control

Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Confocal laser scanning micrographs showing the effects of CD101 and fluconazole on adhesion-phase C. albicans biofilms. Top-down three-dimensional views of biofilms formed by C. albicans treated with no drug (control) (A), 0.25 μg/ml CD101 (B), 1 μg/ml CD101 (C), 1 μg/ml fluconazole (D), or 4 μg/ml fluconazole (E). Thicknesses of Candida biofilms exposed to CD101 (F) or fluconazole (G). *, P value for comparison with the untreated control.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques: Control, Comparison

Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Effects of CD101 and fluconazole on mature-phase C. albicans biofilms (treatment). Effects of CD101 (0.25 or 1 μg/ml) (A) and fluconazole (1 or 4 μg/ml) (B) on metabolic activity of C. albicans biofilms compared to that of the untreated controls. *, P value for comparison with untreated control.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques: Activity Assay, Comparison, Control

Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Confocal laser scanning micrographs showing the effects of CD101 and fluconazole on mature-phase C. albicans biofilms. Top-down three-dimensional views of biofilms exposed to no drug (A), 0.25 μg/ml CD101 (B), 1 μg/ml CD101 (C), 1 μg/ml fluconazole (D), or 4 μg/ml fluconazole (E). Arrows show bulged/broken cells. Thicknesses of Candida biofilms exposed to CD101 (F) or fluconazole (G). *, P value for comparison with untreated control.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques: Comparison, Control

Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Temporal effect of CD101 (0.25 μg/ml) on formation of C. albicans biofilms. Images were captured immediately (at 0 h) and after 16 h for untreated biofilms and those treated with 0.25 μg/ml CD101 (at ×20 and ×63 magnifications). Arrows show bulging, deformed, and broken cells. The time-lapse movies of the effect of CD101 on C. albicans biofilms and of the untreated control can be seen in Movies S1, S2, and S3 in the supplemental material.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques: Control

Journal: Antimicrobial Agents and Chemotherapy

Article Title: CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms

doi: 10.1128/AAC.01750-17

Figure Lengend Snippet: Temporal effect of CD101 (0.25 μg/ml) on 3-h-formed C. albicans biofilms. Drug was added after 3-h biofilm formation, and images were captured immediately after adding the drug (A) and after 16 h (B) (magnification, ×63). Arrows show bulging, deformed, and broken cells. The time-lapse movie of the effect of CD101 on 3-h-formed C. albicans biofilms can be seen in Movie S4.

Article Snippet: CD101 powder was provided by Cidara Therapeutics (San Diego, CA), while fluconazole, which was used as a comparator, was purchased from Sigma-Aldrich (St. Louis, MO).

Techniques:

Journal: Microorganisms

Article Title: Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

doi: 10.3390/microorganisms9040863

Figure Lengend Snippet: Minimum inhibitory concentration (MIC) values of rezafungin (RZF), anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) in RPMI-1640−/+ 50% human serum against Candida auris isolates and type strain. MICs were determined three times using the Clinical Laboratory Standars Institute broth macrodilution method.

Article Snippet: Rezafungin pure powder was provided by Cidara Therapeutics (San Diego, CA, USA).

Techniques: Concentration Assay

Journal: Microorganisms

Article Title: Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

doi: 10.3390/microorganisms9040863

Figure Lengend Snippet: Time-kill plots of rezafungin (RZF), anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) in RPMI-1640 (RPMI) and RPMI-1640 plus 50% human serum (50% serum) against Candida auris isolate I-172, belonging to the South American clade.

Article Snippet: Rezafungin pure powder was provided by Cidara Therapeutics (San Diego, CA, USA).

Techniques:

Journal: Microorganisms

Article Title: Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

doi: 10.3390/microorganisms9040863

Figure Lengend Snippet: Average time (hours) to reach 50% growth reduction (T 50 = 0.30103/ k ) from the starting inocula at different rezafungin (RZF), anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) concentrations in RPMI-1640 −/+ 50% human serum against 4 Candida auris clades. Data of the type strain (NCPF 13029 = CBS 10913) were not included in the data of the East Asian clade. Data in bold indicate that k values were positive (indicating killing) for all isolates within a clade, all other data (nonbold) indicate that one or two isolates never reached 50% growth reduction; the datum represents the average of those isolates in which the 50% growth reduction was reached. NA: 50% growth inhibition not achieved; ND: not determined.

Article Snippet: Rezafungin pure powder was provided by Cidara Therapeutics (San Diego, CA, USA).

Techniques: Inhibition

Journal: Microorganisms

Article Title: Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

doi: 10.3390/microorganisms9040863

Figure Lengend Snippet: Mean killing rate values of rezafungin (RZF), anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) in RPMI-1640 (RPMI) and RPMI-1640 plus 50% human serum (50% serum) against 4 Candida auris clades. Data of the type strain (NCPF 13029 = CBS 10913) were not included in the East Asian clade. Positive and negative k values indicate the decrease and increase, respectively, in viable cell numbers. Error bars were omitted for better visualization of the graphics.

Article Snippet: Rezafungin pure powder was provided by Cidara Therapeutics (San Diego, CA, USA).

Techniques:

Journal: Microorganisms

Article Title: Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

doi: 10.3390/microorganisms9040863

Figure Lengend Snippet: Phase-contrast microscopy images of untreated C. auris cells and cells treated with 16 mg/L rezafungin (RZF), 16 mg/L anidulafungin (ANF), 16 mg/L caspofungin (CSF), and 16 mg/L micafungin (MCF) in RPMI-1640 and RPMI-1640 plus 50% human serum (50% serum) against isolates 204 (South African clade), I-172 (South American clade) and 12,372 (East Asian clade). The micrograph was taken after 24 h. In RPMI-1640, single and budding cells or short chains with small aggregates containing up to 3–6 cells were observed in controls. In 50% serum, the appearance of the untreated isolates was similar, but small aggregates (up to 5–10 µm in diameter) were more frequently observed. In RPMI-1640, all four echinocandins induced large aggregates in the case of isolate I-172, and ANF and MCF in the case of isolate 204, while CSF and MCF in the case of isolate 12372. In 50% serum, large aggregates could be observed only in cases of isolate 204 with CSF and MCF, and isolate I-172 with CSF. Abnormal cell morphology and cell debris were typical after 24 h. Bar: 10 µm.

Article Snippet: Rezafungin pure powder was provided by Cidara Therapeutics (San Diego, CA, USA).

Techniques: Microscopy

Journal: Pathogens and Immunity

Article Title: Time to Think Antifungal Resistance Increased Antifungal Resistance Exacerbates the Burden of Fungal Infections Including Resistant Dermatomycoses

doi: 10.20411/pai.v8i2.656

Figure Lengend Snippet: Antifungal Development and Approvals for Therapeutics Available in the Market by Various Pharmaceutical Industry Members

Article Snippet: , Rezzayo , Rezafungin , 03/01/2023 , Melinta therapeutics.

Techniques: Cream, Suspension